SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

02 May 2024 Evaluate
The company witnessed a 9.10% growth in the revenue at Rs. 9260.70 millions for the quarter ended March 2024 as compared to Rs. 8488.60 millions during the year-ago period.Good  Net Profit growth of 38.80% reported above the corresponding previous quarter figure of Rs. 1172.10 millions to Rs. 1626.90 millioins.The company reported a good operating profit of 2608.30 millions compared to 1812.80 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 9260.70 8488.60 9.10 39711.20 34112.70 16.41 39711.20 34112.70 16.41
Other Income 336.80 367.50 -8.35 1164.80 1327.50 -12.26 1164.80 1327.50 -12.26
PBIDT 2608.30 1812.80 43.88 12359.10 8320.30 48.54 12359.10 8320.30 48.54
Interest 14.20 12.10 17.36 68.00 52.30 30.02 68.00 52.30 30.02
PBDT 2594.10 1800.70 44.06 12291.10 8268.00 48.66 12291.10 8268.00 48.66
Depreciation 334.70 321.10 4.24 1321.60 1269.50 4.10 1321.60 1269.50 4.10
PBT 2259.40 1479.60 52.70 10969.50 6998.50 56.74 10969.50 6998.50 56.74
TAX 632.50 307.50 105.69 2897.10 1411.30 105.28 2897.10 1411.30 105.28
Deferred Tax 34.20 -84.50 -140.47 121.30 -29.30 -513.99 121.30 -29.30 -513.99
PAT 1626.90 1172.10 38.80 8072.40 5587.20 44.48 8072.40 5587.20 44.48
Equity 252.70 252.70 0.00 252.70 252.70 0.00 252.70 252.70 0.00
PBIDTM(%) 28.17 21.36 31.89 31.12 24.39 27.60 31.12 24.39 27.60

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×